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Background: One of the major reasons to stop antibiotic prophylaxis (AP) to prevent infective endocarditis (IE) 
in the United Kingdom but not in the rest of the world was that it would result in more deaths from fatal adverse 
drug reactions (ADRs) than the number of IE deaths. The main aim of this study was to quantify and describe the 
ADRs with amoxicillin or clindamycin for IE AP. The second aim was to infer a crude incidence of anaphylaxis 
associated with amoxicillin for IE AP. 
Study design: The Medical Dictionary for Regulatory Activities (MedDRA) was used to group ADRs for IE AP 
using the broad Standardized MedDRA Queries “Anaphylactic reaction, Amoxicillin, Clindamycin, Clostridium 
Difficile infection” to the French Pharmacovigilance Database System. From this first-line collection, we selected 
all cases occurring for IE AP and ultimately, the cases for IE AP for a dental procedure. Then, each case was 
analyzed. 
Results: Of 11639 first-line recorded ADRs, 100 were for IE AP but no fatal anaphylaxis to amoxicillin or 
clindamycin and no C. difficile infection associated with clindamycin were identified. Only 17 cases of anaphy-
laxis to amoxicillin related to dental procedures were highlighted. The estimation of the crude incidence rate of 
anaphylaxis associated with amoxicillin for IE AP for invasive dental procedure was 1/57 000  (95% CI 0.2-0.6).
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Introduction
Prevention of infective endocarditis (IE) is mainly 
based on antibiotic prophylaxis (AP) in patients with 
predisposing cardiac conditions undergoing invasive 
procedures responsible for bacteremia. This IE AP has 
been recommended since 1955 in the USA (1). Regular-
ly updated over the past few decades, guidelines for IE 
AP are not concordant in every countries. In the United 
Kingdom (UK), the National Institute for health and 
Care Excellence (NICE) recommended complete ces-
sation of any IE AP in any circumstances in 2008 until 
recently (2). In 2016, this institute amended its position, 
stipulating that in individual cases where the risk of IE 
posed to the patient is perceived as sufficiently high, or 
when patients themselves express a preference for it, AP 
may be appropriate (3). The rest of the world restricts 
systematic AP to patients with predisposing cardiac 
conditions at highest risk of IE undergoing the most in-
vasive procedures (American Heart Association: AHA 
in 2007) (4); European Society of Cardiology: ESC 
in 2009, updated in 2015 (5); French National Agen-
cy for Drug Safety: ANSM 2011) (6). All agree on 3 
highest-risk predisposing cardiac conditions (prosthetic 
valve, previous IE, cyanotic congenital heart disease) 
and AP regimen (a single 2-g amoxicillin oral dose 1 
h preoperative, or a 600-mg oral dose of clindamycin 
in penicillin-allergic individuals, in adults). AHA also 
lists cardiac transplantation recipients who develop car-
diac valvulopathy as high-risk of IE patients (4). The 
discrepancy between the British guidelines and the rest 
of the world is mainly based on the assessment of the 
benefit of IE AP. 
The development of drug-resistant strains of oral bacte-
ria, rare but potentially lethal drug reactions and more 
common adverse drug reactions (ADRs) such as gas-
trointestinal upset and the significant cost of antibiotics 
used for IE AP are claimed to outweigh the benefit of 
such AP (7). Even more, for the NICE, the risk that the 
number of deaths from anaphylaxis associated with IE 
AP, amoxicillin prophylaxis in particular, could exceed 
the number of deaths from IE that might be prevented 
by such IE AP (2). But data on fatal outcomes after IE 
AP seem to be very seldom.
In 2007, after oral intake for IE AP, the AHA was un-
aware of any cases of fatal anaphylaxis resulting from 
the administration of penicillin (including amoxicillin) 
recommended in the AHA guidelines for 50 years (4). 
Based on the Medicines and Healthcare products Regu-
Conclusions: Fatal or severe ADRs with amoxicillin or clindamycin is not a rational argument to stop IE AP before 
invasive dental procedures. 
 
Key words: Infective endocarditis, antibiotic prophylaxis, anaphylaxis, adverse drug reaction, amoxicillin, clindamy-
cin, pharmacovigilance.
latory Agency (MHRA) database, Lee and Shanson re-
ported no fatal cases with the single 3 g oral dose of 
amoxicillin in the UK between February 1972 and May 
2007 (8). However, other ADRs than fatal anaphylaxis 
are not documented in these papers. The NICE group, 
preparing clinical guidelines, reported that considering 
IE AP, no episode of anaphylaxis (whatever its degree 
of severity) to amoxicillin had been identified in the lit-
erature (2). Recently, also using the MHRA database 
between January 1980 and January 2014, no fatal reac-
tion following a single 3-g oral dose used for IE AP was 
recorded (9). In addition, 67 non-fatal reactions, 16 of 
which were immune system disorders and 38 allergy-re-
lated skin disorders, were reported in the same period (9). 
Data on severe or fatal outcomes after oral clindamy-
cin intake for IE AP are also very seldom. One fatal 
case of documented Clostridium difficile colitis after 
a single dose of IE prophylactic clindamycin was pub-
lished in 2001 (10). In the study of Thornhill et al., 15 
fatalities were recorded with a single 600-mg oral dose 
of clindamycin used for IE AP, mostly related to C. dif-
ficile infection (9). In addition, 178 non-fatal reactions, 
mostly gastrointestinal or allergy skin disorder reac-
tions, were reported in the same period (9).
Except the case report of Bombassaro et al. (10), none of 
these papers focused on IE AP for invasive dental pro-
cedures as they also included IE AP for gastrointestinal, 
genitourinary or other interventional procedures. To 
date, no investigation of ADRs following oral admin-
istration of the two recommended antibiotics for IE AP, 
i.e., amoxicillin or clindamycin, specifically devoted to 
invasive dental procedures is available. 
The first aim of this study was to quantify and describe 
anaphylactic reactions to amoxicillin or clindamycin 
and C. difficile infections related to clindamycin for 
IE AP for invasive dental procedures recorded in the 
French Pharmacovigilance Database System (FPDS) 
over a 31-year period. The second aim was to infer a 
crude incidence rate of severe or fatal ADRs associated 
with IE AP for invasive dental procedures correlating 
this number of cases to IE AP prescriptions in France 
over a similar period (11).  
Material and Methods
-Study design
The FPDS records all ADRs reported spontaneously 
by healthcare professionals collected by the 31 French 
regional pharmacovigilance centers since 1985 (12). 
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This reporting is entirely voluntary. Every ADR report 
is analyzed by pharmacologists in the regional phar-
macovigilance center. Causality is assessed for every 
suspected drug according to the French imputability 
method (13). ADRs are then registered in the FPDS and 
encoded according to the MedDRA classification. 
-Data collection
First, we collected all anaphylactic reactions to both 
antibiotics, amoxicillin and clindamycin, recorded in 
the FPDS from September 1985 to July 2015 using the 
broad SMQ “Anaphylactic reaction”. SMQs are tools 
developed to facilitate retrieval of MedDRA-coded 
data as a first step in investigating drug safety issues 
in pharmacovigilance and clinical development. SMQs 
are validated, predetermined sets of MedDRA terms 
grouped together after extensive review, testing, analy-
sis and discussion with experts (14). For this study, the 
diagnosis was established by applying criteria from the 
second symposium on the definition and management 
of anaphylaxis (15). 15According to this definition, ana-
phylaxis is a serious systemic reaction fulfilling at least 
one of the three following clinical criteria:
• Acute onset of an illness (within minutes to several 
hours) with involvement of the skin, mucosal tissue or 
both and respiratory compromise or reduced blood pres-
sure or associated symptoms of end-organ dysfunction;
• Occurrence of two or more of the following signs, 
which occur rapidly, after exposure to a likely aller-
gen for that patient (within minutes to several hours): 
involvement of the skin-mucosal tissues, respiratory 
compromise, reduced blood pressure or associated 
symptoms or persistent gastrointestinal symptoms; 
• Reduced blood pressure after exposure to a known al-
lergen for that patient (within minutes or several hours): 
infants and children: low systolic blood pressure (age-
specific) or a > 30% drop in systolic blood pressure; 
adults: systolic blood pressure < 90 mmHg or > 30% 
decrease from that person’s baseline.    
From this first-line collection, we selected all cases oc-
curring for IE AP and ultimately, the cases for IE AP 
for a dental procedure. We classified all these reports 
according to the Ring and Messmer severity scale of 
anaphylactoid reaction (Table 1) (16). 
An additional request was made to extract cases of C. 
difficile infection related to clindamycin.
Grade Symptoms
I Skin symptoms and/or mild fever reaction
II Measurable but not life-threatening cardiovascular reaction (tachycardia, 
hypotension), gastrointestinal disturbance (nausea) or respiratory disturbance
III Shock, life-threatening spasm of smooth muscles (bronchi, uterus, etc.)
IV Cardiac and/or respiratory arrest
Table 1. Severity scale of anaphylactoid reaction (according to Ring and Messmer) (16).
-Data analysis
For each case, the following data were collected: gen-
der, age, clinical features, severity of symptoms, emer-
gency treatment, possible risk factors of anaphylaxis, 
any associated medications and results of allergy test-
ing (first-line tests: skin prick test (SPT) and intrader-
mal test (IDT); second-line tests: specific IgE assay and 
basophil activation test (BAT) when available). 
Descriptive statistics were performed using Microsoft 
Excel 2007 (Microsoft Corporation, France). We calcu-
lated numbers and percentages for each variable, mean 
± standard deviation (SD). Statistical analysis was per-
formed using the Student t-test. We considered p<0.05 
to be statistically different. 
Results 
-Case selection
The first-line search identified a total of 11 061 cases 
of anaphylactic reactions to amoxicillin declared to the 
FPDS during this 31-year period by the broad SMQ 
“anaphylactic reaction”. This number decreased to 100 
when targeting the selection on IE AP and after elimi-
nation of duplicates. Sixty four of them were classified 
as grade I, 21 as grade II, 13 as grade III and 2 as grade 
IV (Fig. 1). When restricting to dental procedures, this 
number fell to 17 cases (grade I: 3; grade II: 1; grade III: 
11 and grade IV: 2)  (Fig. 1). No case of fatal anaphy-
laxis with amoxicillin for IE AP was recorded for any 
type of procedure. 
Using the same methodology, the first-line search iden-
tified a total of 536 cases of anaphylactic reactions to 
clindamycin. In addition, 42 cases of C. difficile infec-
tion were recorded when applying the supplementary 
request. However, when applying eligibility criteria – 
IE AP – no case of anaphylaxic reaction or C. difficile 
infection was selected.
-Demographics 
The age of the 17 selected patients varied from 25 to 85 
years (49.43 ± 16.28); 10 were younger than 50 years old. 
No case was recorded in the young adult or pediatric 
populations. There was an overall female predominance 
(58.82%, p<0.01) (Table 2). All the 17 cases selected were 
equally disseminated along the 31-year research period. 
Fifteen of them were patients with prosthetic heart valves 
and 2 patients had experienced previous IE. 
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Fig. 1. Flow chart of case selection for amoxicillin anaphylaxis. Grades of severity accord-
ing to Ring and Messmer (16).
-Clinical features
According to the Ring and Messmer classification, 3 of 
these 17 cases of amoxicillin anaphylaxis was classified 
as grade I because only affected by skin symptoms, 1 
as grade II because affected by respiratory disturbance, 
11 as grade III because having exhibited shock or life-
threatening spasm of smooth muscles (mainly bronchi) 
and 2 as grade IV because cardiac arrests were report-
ed. All the patients were hospitalized in an emergency 
department but only two of them were directly admitted 
in an intensive care unit. Corticoids, mostly intravenous 
prednisolone, associated or not with antihistaminics, 
were used in the majority of the cases and intramuscular 
epinephrine in the two most severe cases (Table 3). The 
outcome of these 17 cases was complete recovery. As-
sociated drugs that were potential risk factors enhanc-
ing the severity of anaphylaxis were recorded in four 
cases, NSAIDs (two cases), ß-blockers (one case) and 
an association of angiotensin II receptor antagonist with 
calcium antagonist (one case) (Table 2).  
Various clinical features were observed (Table 3). Cu-
taneous symptoms (urticaria, erythema, angioedema) 
were present in all but one case. Cardiovascular symp-
toms such as hypotension or collapse (but no cardiac 
arrest) were reported in 11 cases. Respiratory distur-
bances, mainly bronchospasms (but no respiratory ar-
rest), were reported in 4 cases.  
-Allergy history
Comorbidities such as atopic eczema/dermatitis, aller-
gic seasonal rhinitis and asthma were reported in seven 
cases (Table 2). No food intolerance was recorded. One 
case of cross-reactivity with diclofenac was recorded 
(case 16). Interestingly, 11 patients reported a history of 
previous medication with amoxicillin, seven of which 
had had good tolerance (Table 2).
-Allergy tests
First-line skin tests, SPT or IDT, for amoxicillin were 
available for 14 of 17 patients (Table 4). The SPT was 
positive in seven cases and IDT in four cases. A specific 
IgE assay was performed in eight patients and three 
were positive. In patients with negative specific IgE as-
says, the diagnosis of non-IgE-mediated hypersensitiv-
ity reaction was established. A BAT was available in 
four cases and positive in two of them.
-Estimation of crude incidence rate of anaphylaxis as-
sociated with IE AP for invasive dental procedures
In a recent French crossover study, 138 876 patients 
with prosthetic heart valves (285 084 person-year) were 
included from January 2006 to December 2014 with a 
median follow-up of 1.7 year (11). During this 9-year 
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Patient Age Gender Familial history of 
allergy to amoxicillin





1 46 F NA Yes: well tolerated No No
2 25 M NA NA No No
3 58 F NA NA NA No
4 44 M NA Yes: well tolerated NA No
5 85 F NA NA NA No
6 44 M NA Yes: urticaria Yes: penicillin Atenolol
(b-blocker)
7 55 F Yes: mother, brothers 
and sister
Yes: well tolerated Yes: pollen No
8 57 F NA Yes: well tolerated Yes: latex No
9 40 F NA Yes: urticaria Yes: penicillin Ketoprofen
(NSAID)
10 36 M Yes: father NA No No
11 63 F NA Yes: pruritis Yes: penicillin No
12 36 M NA Yes: well tolerated Yes: pollen Celecoxib
(NSAID)
13 74 M No Yes: well tolerated No No
14 42 F Yes: grandmother NA No No
15 63 M NA Yes: well tolerated NA Valsartan (ARA)
Lercanidipine
(Ca antagonist)
16 40 F NA Yes: well tolerated Yes: pollen and 
diclofenac
No
17 33 F NA NA NA No
Table 2. Demographic characteristics and allergy history. 
F: female; M: male; NA: not available; NSAID: nonsteroidal anti-inflammatory drugs; ARA: angiotensin receptor antagonist.
period, 103 463 invasive dental procedures of which 52 
280 (50.1%) were covered by IE AP which represent a 
total of 276 776 (1.7/9 x 52 280) invasive dental proce-
dures if each of these patients would have a 9 year fol-
low-up.  Only 82.2% of these procedures were covered 
by amoxicillin IE AP which represent a total of 227 510 
procedures. During the same period, 4 of the 17 selected 
cases in FDPS were recorded, all of them with amoxi-
cillin in patients with prosthetic heart valves, so that 
the estimation of a crude incidence rate of amoxicillin 
anaphylaxis for IE AP for invasive dental procedures is 
4//227 510 and so 1/57 000 (95% CI 0.2-0.6). 
Discussion
The main result of this study is the lack of fatal ana-
phylaxis with amoxicillin or clindamycin and C. diffi-
cile infections with clindamycin related to IE AP over 
a long 30-year period in France. Moreover, in patients 
with prosthetic heart valves undergoing dental proce-
dures, the estimation of the risk of developing an ana-
phylaxic reaction with amoxicillin in this IE AP indica-
tion (1/57,000) appears lower than the risk of developing 
IE (1/46,000) (17).  
In 1984, Bor and Himmelstein calculated a quantitative 
estimation of the risks and benefits of IE AP using peni-
cillin for patients with mitral valve prolapse undergoing 
a dental procedure on the basis of published data, and 
the response to a questionnaire concluded that risks of 
IE AP outweighed its benefits (18). However, this con-
clusion cannot be worthy of consideration today since 
mitral valve prolapse is not a PCC at high risk of IE and 
penicillin G or V is no longer recommended for IE AP. 
Devereux et al. estimated that fatal allergic reactions to 
oral amoxicillin for IE AP in patients with mitral valve 
prolapse occurred with a frequency of 0.9 per million 
patients for IE AP (19). However, this estimation, de-
rived from a study by Clemens and Ransohoff (20), was 
more related to penicillin than amoxicillin, considering 
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Patient Clinical features Emergency treatment Grade of severity
(Ring & 
Messmer) (16)
1 Pruritis Antihistaminic I
2 Pruritis, angioedema Methylprednisolone II
3 Angioedema Prednisolone, antihistaminic I
4 Angioedema Antihistaminic I
5 Erythema, vomiting, bronchospasm Methylprednisolone III
6 Angioedema, hypotension Prednisolone, antihistaminic III
7 Angioedema, hypotension Prednisolone, antihistaminic III
8 Urticaria, pruritis, hypotension, diarrhea Betamethasone III
9 Angioedema, urticaria, bronchospasm Prednisolone, antihistaminic III
10 Erythema, pruritis, hypotension Methylprednisolone III
11 Erythema, pruritis, hypotension, bronchospasm Methylprednisolone III
12 Rash, pruritis, hypotension Antihistaminic III
13 Angioedema, urticaria, erythema, hypotension Prednisolone III
14 Pruritis, diarrhea, hypotension Antihistaminic III
15 Angioedema, rash, hypotension, tachycardia, syncope Methylprednisolone, Epinephrine IV
16 Angioedema, urticaria, hypotension, bronchospasm Prednisolone, Epinephrine IV
17 Rash, hypotension Antihistaminic III
Table 3. Amoxicillin anaphylaxis characteristics.
Patient SPT IDT IgE BAT
1 P NA NA NA
2 N N N NA
3 P NA N NA
4 NA NA NA NA
5 NA NA NA NA
6 N P (1/100) P (0.30 kU/L) P (43%)
7 N P (1/100) N NA
8 P NA P (0.48 kU/L) NA
9 N N N P
10 N N NA NA
11 P P (1/100) NA NA
12 NA N NA NA
13 N N N N
14 N N NA NA
15 P NA NA NA
16 P P (1/1000) P (0.20 kU/L) N
17 P NA NA NA
Table 4. Allergy tests.
SPT: skin prick test; IDT: intradermal test; IgE: specific immunoglobuline E assay; 
BAT: basophil activation assay; NA: not available; N: negative; P: positive.
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dose, duration and route of administration. Once again, 
it was in patients for whom IE AP is no more required 
according to the ESC current guidelines.  
Considering IE AP using only oral amoxicillin, fatal 
anaphylaxis has not yet been reported in the literature 
in either the USA (4), or the UK (8,9), or elsewhere in 
the world. Indeed, the AHA has failed to report fatal 
anaphylaxis associated with IE AP in the USA for the 
last 50 years where amoxicillin has been the mainstay 
of the recommended regimens (4), even if it was esti-
mated a few decades ago that 1.36 people per million 
are likely to die annually from penicillin anaphylaxis to 
prevent IE, whereas not more than 0.26 annual deaths 
per million population are traceable to IE from dental 
procedures (21). This does not support the estimation of 
Seymour et al. that patients receiving penicillin (amoxi-
cillin) prophylaxis to prevent IE are five times more 
likely to die from an anaphylactic reaction to the drug 
than to die from IE contraction (22). In a recent study 
also using the MHRA database, 73 fatal and 3072 non-
fatal reports related to all doses, durations and routes of 
administration of amoxicillin as a single active constit-
uent were reported from July 1963 to August 2014 (9). 
During the data-recording period from January 1980 to 
January 2014, this study did not reveal fatal reaction to 
a single 3-g oral dose of amoxicillin (dosage schedule 
and route of administration almost exclusively used for 
AP purposes) but revealed 67 nonfatal reaction reports 
(9). Consequently, the fatal and nonfatal ADR rates per 
million amoxicillin prescriptions were 0 and 22.6, re-
spectively, which is very low, as also illustrated by the 
1/57,000 estimation of the crude incidence rate of amox-
icillin anaphylaxis in the present study for invasive den-
tal procedures. This estimation should be compared to 
incidence rates for all-cause anaphylaxis ranging from 
1.5 to 7.9 person-years in Europe (23), or 3.2 to 49.8 per-
son-years worldwide (24). These incidences appear to 
be increasing in recent years and drug-induced anaphy-
laxis in particular. Ultimately, the AHA committee (and 
other agencies recommending IE AP for invasive dental 
procedures) believes that a single dose of amoxicillin is 
safe and is the preferred prophylactic agent for individu-
als who do not have a history of type I hypersensitivity 
reaction to a penicillin, such as anaphylaxis, urticaria or 
angioedema (4).  
Regarding clindamycin, its association with C. dif-
ficile infection is well established even following a 
single dose administration (25). Only one case specifi-
cally related to the use of clindamycin for IE AP for 
a dental procedure has been reported in the literature 
(10). However, the occurrence of severe anaphylaxis to 
this molecule is thought to be rare (26). With a single 
600-mg oral dose of clindamycin (dosage schedule and 
route of administration almost exclusively used for AP 
purposes), a UK survey based on the MHRA database 
from January 1969 to January 2014 revealed 15 fatal re-
actions (of which 12 were due to C. difficile infections) 
and 178 nonfatal reactions (one immune and 60 allergy-
related skin disorder reactions) (9). In this study, the fa-
tal and nonfatal ADR rates per million clindamycin pre-
scriptions were 12.6 and 149.1, respectively, higher than 
those with amoxicillin (0 and 22.6, respectively) (9). In 
the present study, unlike Thornhil et al., we recorded 
no fatalities associated with clindamycin for IE AP and 
many fewer nonfatal ADRs. However, it seems that the 
use of clindamycin for AP carries a significant risk of 
ADRs that need to be confirmed by additional studies. 
It must be remembered that clindamycin use for IE AP 
is only recommended as an alternative prescription in 
case of allergy to amoxicillin. Moreover, in France, 
clindamycin IE AP represents only 1% of the total IE 
AP, which probably minors the number of ADRs related 
to this molecule compared to what is observed in UK.
According to the current guidelines for management of 
anaphylaxis, epinephrine was used as emergency treat-
ment in the most severe cases and a corticosteroid in the 
majority of the other cases (27). Cases with only cutane-
ous features were mainly managed with antihistaminic 
alone. Associated drugs, being potential risk factors 
enhancing the severity of anaphylaxis were recorded 
for four cases. Analysis of the reports highlighted co-
morbidity factors and particularly co-prescription of a 
NSAID, a well-documented family of drugs involved 
in anaphylactic reactions in such a way that the sole re-
sponsibility of amoxicillin in these reactions remains 
elusive.    
Drug anaphylaxis is rarely documented by allergy tests, 
which may provide more information and thus prevent 
further reactions. Skin testing is the basic diagnostic 
tool but with several limits. Both SPTs and IDTs for 
amoxicillin were performed for the 15 patients of this 
study. Positive SPTs were associated with seven cases, 
whereas positive IDTs were recorded in four cases. Con-
cordance between the two tests has only been observed 
in seven cases, two positive and five negative. This dis-
crepancy is also recorded in a recent study investigat-
ing 333 cases of severe drug-induced anaphylaxis, of 
which 97 were related to amoxicillin. Only 50% of them 
showed a positive SPT, whereas 40.5% were associated 
with a negative SPT but a positive IDT (28). Moreover, 
skin test sensitivity for ß-lactams varied widely in dif-
ferent populations but also over the years. In a survey 
of 24 patients with a positive SPT to amoxicillin, only 
50% of them were still positive after 1 year and none 
at 5 years, so that the efficiency of skin tests remains 
questionable for the diagnosis of anaphylaxis to amoxi-
cillin (29). In vitro tests such as detection of specific IgE 
antibodies to ß-lactams in serum using immunoassays 
and detection on the basis of basophil activation are 
techniques considered to be complementary to in vivo 
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tests, but in patients with severe anaphylactic reactions, 
the in vitro test should be the first choice in the diag-
nosis evaluation (29). This recommendation is probably 
too recent to be applied to all the patients of this study, 
but we noted that all the most recent patients except 
one were well documented. Hypersensitivity reactions 
to ß-lactams are classified as immediate when appear-
ing within 1h of drug-intake and they are mediated by 
specific IgE-antibodies (30), and delated reactions are 
those occurring usually more than 1h after drug intake 
and are not IgE mediated (31). Moreover, both clinical 
patterns associating urticaria with angioedema (as re-
corded for patients 9, 13 and 16) are considered as more 
specific of an IgE-mediated reaction (31). However, the 
specific IgE assay was negative for patients 9 and 13, 
so that the sensitivity and/or the specificity of the tests 
calculated for these patients remain questionable. Taken 
together, these data highlight the need for future re-
search to focus on optimizing diagnostic protocols and 
understanding anaphylaxis related to IE AP.
Our study has a number of unavoidable methodological 
drawbacks, as do most pharmacovigilance studies ex-
amining spontaneous notification. Reporting by health 
professionals is entirely voluntary and not all ADRs are 
reported, while those reported may omit relevant data 
(such as IE AP indication or route of administration), or 
may be cofounded by other factors. Many authors spec-
ulate that the prevalence of ADRs is underestimated 
from underreporting (32-34). In France, it has been esti-
mated that less than 5% of all ADRs are spontaneously 
reported to the FPDS (32). But healthcare profession-
als are more likely to report a serious or fatal suspected 
ADR than a nonserious reaction. On another side, the 
reporting of ADRs for older drugs such amoxicillin is 
much lower than that for newer drugs (34). Consequent-
ly, based on available data, we can only speculate about 
the true incidence of antibiotic-induced ADRs, particu-
larly anaphylaxis for IE AP.  
Conclusions
The NICE guidance and others suggest that the risk of 
fatal anaphylaxis from amoxicillin prophylaxis is so 
great that it would result in more deaths from anaphy-
laxis than the number of IE deaths prevented by giv-
ing AP. However, this fear is probably exaggerated, as 
there have been no reports of deaths from anaphylaxis 
following amoxicillin prophylaxis against IE, particu-
larly related to invasive dental procedures, as shown by 
this study. IE AP with clindamycin could be a greater 
source of ADRs including fatalities. Unless convinc-
ing data are obtained from future research, consensus 
guidelines will continue to be based mainly on expert 
opinion rather than on hard evidence. This is not to say 
that fatal ADRs to amoxicillin and clindamycin does 
not exist, given the limitations of this study, but this ar-
gument cannot rationally be retained to stop IE AP. Ul-
timately, IE AP for invasive dental procedures appears 
to be safe and should be strengthened for predisposing 
cardiac conditions at high IE risk. 
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